MitoRx Therapeutics develops first-in-class small molecule therapeutics that modulate mitochondrial metabolism to address cardiometabolic diseases, starting with obesity. Their platform utilizes targeted compounds to restore sulfide-signaling via enzymatic release within the mitochondria, reversing dysfunction. This approach aims to provide anti-obesogenic effects while preserving lean mass through adaptive metabolism restoration.
Funding
$6.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
UIFounders
Product
Problem
Many progressive diseases, such as obesity-related conditions and myopathies, are characterized by mitochondrial dysfunction resulting from trans-sulfuration deficiency. This deficiency impairs sulfide-signaling, leading to muscle weakness, muscle wasting, cognitive deficits, and neurodegeneration. Current treatments do not directly address the underlying mitochondrial dysfunction in these diseases.
Solution
MitoRx Therapeutics is developing a mitochondriotropic platform that utilizes mitochondrial-targeted sulfide donors (mtH2SDs) to restore sulfide-signaling and reverse mitochondrial dysfunction. The mtH2SDs exploit an endogenous mechanism to replenish sulfide, which is deficient in several diseases, thereby restoring adaptive metabolism. This approach aims to halt or reverse the progression of degenerative conditions by overcoming mitochondrial-driven disease states. The company's first-in-class, first-in-mechanism therapeutics are designed for safe enzymatic release within the mitochondria, avoiding rapid systemic release.
Target Audience
The primary target audience includes patients suffering from obesity-related diseases, myopathies such as Duchenne muscular dystrophy, lung inflammatory diseases, and neurodegenerative diseases like Parkinson's and Alzheimer's.
Features
- Proprietary mtH2SD technology targeting mitochondrial metabolic transactivators
- Designed to act at epigenetic, transcriptional, and post-translational levels
- Enzymatic release of H2S within the mitochondria to replenish substrate required for persulfidation
- Rapid tissue distribution with negligible systemic H2S release
- Demonstrated anti-obesogenic and muscle-protective effects in metabolic disease models
- Potential application in obesity-related indications, myopathies, lung inflammatory diseases, and neurodegenerative diseases